keyword
MENU ▼
Read by QxMD icon Read
search

Metastatic colorectal cancer

keyword
https://www.readbyqxmd.com/read/28329488/capecitabine-induced-lichenoid-drug-eruption-a-case-report
#1
Jeff R Gehlhausen, Matthew B Strausburg, Mouhammad Aouthmany, Terrence M Katona, Matthew J Turner
Capecitabine is a 5-fluorouracil basedchemotherapeutic drug widely used in the treatmentof solid tumors, especially colorectal and breast. Someof the most common side effects of capecitabine arecutaneous in nature, including hand-foot syndrome(palmar-plantar erythrodysesthesia). Several reports inthe literature link capecitabine use with photosensitivelichenoid eruptions. Herein, we present a case ofcapecitabine-induced lichenoid eruption in an elderlyfemale with metastatic breast cancer and discuss ourfindings in relationship to previously reported cases ofthis and other capecitabine-induced skin pathologies...
February 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28329272/thoracoscopic-surgery-versus-open-surgery-for-lung-metastases-of-colorectal-cancer-a-multi-institutional-retrospective-analysis-using-propensity-score-adjustment%C3%A2
#2
Tomohiro Murakawa, Hajime Sato, Sakae Okumura, Jun Nakajima, Hirotoshi Horio, Yuichi Ozeki, Hisao Asamura, Norihiko Ikeda, Hajime Otsuka, Haruhisa Matsuguma, Ichiro Yoshino, Masayuki Chida, Mitsuo Nakayama, Toshihiko Iizasa, Meinoshin Okumura, Satoshi Shiono, Ryoichi Kato, Tomohiko Iida, Noriyuki Matsutani, Masafumi Kawamura, Yukinori Sakao, Kazuhito Funai, Go Furuyashiki, Hirohiko Akiyama, Shigeki Sugiyama, Naoki Kanauchi, Yuji Shiraishi
OBJECTIVES: Thoracoscopic surgery for lung metastasectomy remains controversial. The study aimed at determining the efficacy of thoracoscopic surgery for lung metastasectomy. METHODS: This was a multi-institutional, retrospective study that included 1047 patients who underwent lung metastasectomy for colorectal cancer between 1999 and 2014. Prognostic factors of overall survival were compared between the thoracoscopic and open thoracotomy groups using the multivariate Cox proportional hazard model...
February 16, 2017: European Journal of Cardio-thoracic Surgery
https://www.readbyqxmd.com/read/28328955/treatment-monitoring-in-metastatic-colorectal-cancer-patients-by-quantification-and-kras-genotyping-of-circulating-cell-free-dna
#3
Andreas W Berger, Daniel Schwerdel, Hanna Welz, Ralf Marienfeld, Stefan A Schmidt, Alexander Kleger, Thomas J Ettrich, Thomas Seufferlein
Treatment of metastatic colorectal cancer (CRC) has continuously improved over the last decade. However, disease monitoring remains underdeveloped and mostly dependent on imaging e.g. RECIST 1.1 criteria. The genetic landscape of individual cancers and subsequently occurring treatment-induced evolution remain neglected in current surveillance strategies. Novel biomarkers demand minimally invasive and repetitive tracking of the cancer mutagenome for therapy stratification and to make prognostic predictions. Carcinoembryonic antigen (CEA), a routinely used tumor marker for CRC, does not meet these goals and thus prevents its use as a reliable monitoring tool...
2017: PloS One
https://www.readbyqxmd.com/read/28328812/overall-survival-of-patients-with-kras-wild-type-tumor-treated-with-folfox-forfiri%C3%A2-cetuximab-as-the-first-line-treatment-for-metastatic-colorectal-cancer-a-meta-analysis
#4
Ya-Fan Yang, Gui-Ying Wang, Jing-Li He, Feng-Peng Wu, Yan-Ni Zhang
The addition of cetuximab to FOLFIRI or FOLFOX as the first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease. An updated systematic meta-analysis was undertaken to determine the efficacy of cetuximab plus FOLFIRI or FOLFOX.Major databases were searched to identify RCTs investigating wild-type KRAS mCRC after the first-line treatment, and treatment with FOLFOX/FORFIRI ± cetuximab was compared...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28327965/carbon-dating-cancer-defining-the-chronology-of-metastatic-progression-in-colorectal-cancer
#5
H Lote, I Spiteri, L Ermini, A Vatsiou, A Roy, A McDonald, N Maka, M Balsitis, N Bose, M Simbolo, A Mafficini, A Lampis, J C Hahne, F Trevisani, Z Eltahir, G Mentrasti, C Findlay, Eaj Kalkman, M Punta, B Werner, S Lise, A Aktipis, C Maley, M Greaves, C Braconi, J White, M Fassan, A Scarpa, A Sottoriva, N Valeri
Background: HASH(0x346fed0) Patients often ask oncologists how long a cancer has been present before causing symptoms or spreading to other organs. The evolutionary trajectory of cancers can be defined using phylogenetic approaches but lack of chronological references makes dating the exact onset of tumours very challenging. Patients and Methods: HASH(0x2edb4f0) Here we describe the case of a colorectal cancer patient presenting with synchronous lung metastasis and metachronous thyroid, chest wall and urinary tract metastases over the course of five years...
February 23, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28327895/cetuximab-rechallenge-in-metastatic-colorectal-cancer-patients-how-to-come-away-from-acquired-resistance
#6
D Santini, B Vincenzi, R Addeo, C Garufi, G Masi, M Scartozzi, A Mancuso, A M Frezza, O Venditti, M Imperatori, G Schiavon, G Bronte, G Cicero, F Recine, E Maiello, S Cascinu, A Russo, A Falcone, G Tonini
No abstract text is available yet for this article.
February 21, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28323034/co-targeting-of-egfr-and-autophagy-signaling-is-an-emerging-treatment-strategy-in-metastatic-colorectal-cancer
#7
Evangelos Koustas, Michalis V Karamouzis, Chrysovalantou Mihailidou, Dimitrios Schizas, Athanasios G Papavassiliou
The epidermal growth factor receptor (EGFR) and its associated pathway is a critical key regulator of CRC development and progression. The monoclonal antibodies (MoAbs) cetuximab and panitumumab, directed against EGFR, represent a major step forward in the treatment of metastatic Colorectal cancer (mCRC), in terms of progression-free survival and overall survival in several clinical trials. However, the activity of anti-EGFR moAbs appears to be limited to a subset of patients with mCRC. Studies have highlighted that acquired-resistance to anti-EGFR MoAbs biochemically converge into Ras/Raf/Mek/Erk and PI3K/Akt/mTOR pathways...
March 18, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28320583/rapid-analysis-of-outcomes-using-the-systemic-anti-cancer-therapy-sact-dataset
#8
R Pathak, M Wallington, C Saunders, M Braun, S Mullamitha, G Wilson, J Hasan, D Dodwell, M Bomb, M Saunders
We audited the accuracy of the Systemic Anti-Cancer Therapy dataset as a resource for rapid analysis of outcomes for patients, in this example, receiving Cancer Drug Fund funded monoclonal antibodies to treat metastatic colorectal cancer. We concluded that the Systemic Anti-Cancer Therapy dataset is a potentially valuable resource for rapidly determining survival outcome for patients treated with chemotherapy.
March 17, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28320104/sulfatase-2-promotes-the-growth-and-metastasis-of-colorectal-cancer-by-activating-akt-and-erk1-2-pathways
#9
Youmao Tao, Tao Han, Tao Zhang, Caixia Sun
The molecular mechanisms underlying the growth and metastasis of colorectal cancer (CRC) remain largely unknown. Sulfatase-2 (SULF2) was found to play critical roles in human cancers. Recent study reported that SULF1/2 overexpression resulted in increased viability and proliferation, and augmented cell migration in CRC cells. However, the expression of SULF2 and its underlying molecular mechanisms in CRC remain unknown. In this study, we found that the expressions of SULF2 in CRC tissues and cell lines were significantly increased compared to control groups...
March 18, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28317063/prognostic-value-of-pretreatment-diffusion-weighted-magnetic-resonance-imaging-for-outcome-prediction-of-colorectal-cancer-liver-metastases-undergoing-90y-microsphere-radioembolization
#10
Frederic Carsten Schmeel, Birgit Simon, Julian Alexander Luetkens, Frank Träber, Carsten Meyer, Leonard Christopher Schmeel, Amir Sabet, Samer Ezziddin, Hans Heinz Schild, Dariusch Reza Hadizadeh
PURPOSE: To investigate the clinical potential of pretreatment apparent diffusion coefficient (ADC) on diffusion-weighted magnetic resonance imaging (DWI) for therapy response and outcome prediction in patients with liver-predominant metastatic colorectal cancer (CRC) undergoing radioembolization with (90)Yttrium-microspheres (90Y-RE). METHODS: Forty-six consecutive patients with unresectable CRC liver metastases underwent standardized clinical DWI on a 1.5 T MR scanner prior to and 4-6 weeks after 90Y-RE...
March 19, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28317047/biliary-metastasis-in-colorectal-cancer-confers-a-poor-prognosis-case-study-of-5-consecutive-patients
#11
Frederick Hong-Xiang Koh, Wang Shi, Ker-Kan Tan
The biliary duct is an extremely rare site for colon cancer metastasis. It often leads to a diagnostic dilemma, since primary cholangiocarcinoma (potentially treatable with surgery) has a similar presentation. This paper highlights our experience with 5 consecutive patients who had colon malignancy with biliary metastasis, and prognosis of their disease. Five patients, with a history of primary colon cancer since 2010, were identified to have biliary metastasis. Of these, 4 (80.0%) patients were male. The median time to diagnosis of biliary metastasis from diagnosis of colon cancer was 59...
February 2017: Ann Hepatobiliary Pancreat Surg
https://www.readbyqxmd.com/read/28315907/can-preoperative-cea-and-ca19-9-serum-concentrations-suggest-metastatic-disease-in-colorectal-cancer-patients
#12
Milica Stojkovic Lalosevic, Sanja Stankovic, Mirjana Stojkovic, Velimir Markovic, Ivan Dimitrijevic, Jovan Lalosevic, Jelena Petrovic, Marija Brankovic, Aleksandra Pavlovic Markovic, Zoran Krivokapic
OBJECTIVE: This study was designed to investigate the efficiency of preoperative serum carcinoembryonic antigen (CEA) and carbohydrate cancer antigen (CA19-9) levels for diagnosing synchronous liver metastases and lymph node in colorectal carcinoma (CRC) patients. SUBJECTS AND METHODS: A total of 300 patients with histologically diagnosed CRC were included in this study between May 2014 and March 2015. The data were obtained prospectively from patient's medical records: medical history, demographics, tumor location, differentiation (grade), depth of the tumor (T), lymph node metastases (N), distant metastases (M), lymphatics, venous and perineural invasion, and disease stage...
March 20, 2017: Hellenic Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28315543/metastatic-colorectal-cancer-management-with-trifluridine-tipiracil%C3%A2
#13
Teresa White, Heidi Larson, Alexandra Minnella, Howard S Hochster
BACKGROUND: Treatment-related adverse events (AEs) are common in patients with metastatic colorectal cancer (mCRC) receiving chemotherapy. These AEs may affect patient adherence, particularly with completely oral regimens, such as trifluridine/tipiracil (TAS-102, Lonsurf®), an antimetabolite agent for patients with mCRC refractory or intolerant to standard therapies.
. OBJECTIVES: This article reviews strategies for promoting adherence and educating patients and caregivers about oral therapy with trifluridine/tipiracil...
April 1, 2017: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/28314765/no-back-seat-for-a-progression-event-k-ras-as-a-therapeutic-target-in-crc
#14
REVIEW
Emily J Poulin, Kevin M Haigis
KRAS is the most frequently mutated oncogene in human cancer and plays a central, although poorly understood, role in colorectal cancer (CRC) progression. In this issue of Genes & Development, Boutin and colleagues (pp. 370-382) present a new mouse model of CRC in which the expression of oncogenic K-RAS is regulated by doxycycline. Using this model, they demonstrate that continued expression of oncogenic K-RAS is required for the survival of primary and metastatic colon cancers and that oncogenic K-RAS activates TGF-β signaling to promote tumor invasion and metastasis...
February 15, 2017: Genes & Development
https://www.readbyqxmd.com/read/28314325/mic1-gdf15-as-a-bone-metastatic-disease-biomarker
#15
Jindra Windrichova, Radka Fuchsova, Radek Kucera, Ondrej Topolcan, Ondrej Fiala, Jindrich Finek, Dagmar Slipkova
AIM: The aim of the study was to evaluate MIC1/GDF15 as a biomarker in the monitoring of bone metastases occurrence. PATIENTS AND METHODS: The assessed group included patients diagnosed with: prostate cancer, breast cancer, lung cancer and colorectal cancer. Patients were divided into two groups based on the scintigraphy of the occurrence of bone metastases. Group 0 contained 55 patients without bone metastases, that served as the control group. Group 1 contained 75 patients with bone metastases...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28314295/development-and-applicability-of-integrative-tumor-response-assays-for-metastatic-colorectal-cancer
#16
Yong Sik Yoon, Chan Wook Kim, Seon Ae Roh, Dong Hyung Cho, Tae Won Kim, Moon Bo Kim, Jin Cheon Kim
AIM: The present study investigated how well the results of integrative tumor-response assay (ITRA) compared to those of clinical response to chemotherapy in patients with metastatic colorectal cancer (CRC). PATIENTS AND METHODS: A total of 129 patients with metastatic CRC were prospectively enrolled. ITRA consisted of two sequential histoculture drug-response assays (HDRAs). First-stage HDRAs were performed using 5-fluorouracil with leucovorin and oxaliplatin (FX), or with irinotecan (FR)...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28303751/vasoactive-peptides-associate-with-treatment-outcome-ofbevacizumab-containing-therapy-in-metastatic-colorectal-cancer
#17
Helga Hagman, Pär-Ola Bendahl, Olle Melander, Jan Sundberg, Anders Johnsson, Mattias Belting
BACKGROUND: Hypertension is a common early adverse event of anti-angiogenic treatment of cancer and may associate with treatment response. However, blood pressure measurement as a surrogate response biomarker has methodological limitations, and predictive biomarkers of angiogenesis inhibitors are lacking. In disease associated with hypertension, vasoactive peptides have been linked to cardiovascular pressure load. Here, we have explored potential associations between circulating levels of vasoactive peptides and tumor response during bevacizumab-containing treatment of colorectal cancer...
March 17, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28302530/regorafenib-overcomes-chemotherapeutic-multidrug-resistance-mediated-by-abcb1-transporter-in-colorectal-cancer-in-vitro-and-in-vivo-study
#18
Yi-Jun Wang, Yun-Kai Zhang, Guan-Nan Zhang, Sweilem B Al Rihani, Meng-Ning Wei, Pranav Gupta, Xiao-Yu Zhang, Suneet Shukla, Suresh V Ambudkar, Amal Kaddoumi, Zhi Shi, Zhe-Sheng Chen
Chemotherapeutic multidrug resistance (MDR) is a significant challenge to overcome in clinic practice. Several mechanisms contribute to MDR, one of which is the augmented drug efflux induced by the upregulation of ABCB1 in cancer cells. Regorafenib, a multikinase inhibitor targeting the RAS/RAF/MEK/ERK pathway, was approved by the FDA to treat metastatic colorectal cancer and gastrointestinal stromal tumors. We investigated whether and how regorafenib overcame MDR mediated by ABCB1. The results showed that regorafenib reversed the ABCB1-mediated MDR and increased the accumulation of [(3)H]-paclitaxel in ABCB1-overexpressing cells by suppressing efflux activity of ABCB1, but not altering expression level and localization of ABCB1...
March 13, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28302003/liver-transplant-for-nonhepatocellular-carcinoma-malignancy
#19
Nihan Haberal Reyhan
Liver transplant is now an acceptable and effective treatment for specific nonhepatocellular malignancies. Worldwide, hilar cholangiocarcinoma accounts for 3% of all primary gastrointestinal malignancies and for 10% of primary hepatobiliary malignancies. For patients who have early-stage, unresectable cholangiocarcinoma, liver transplant preceded by neoadjuvant radiotherapy can result in tumor-free margins, accomplish a radical resection, and treat the underlying primary sclerosing cholangitis when present...
March 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/28299879/how-accurate-are-medical-oncologists-impressions-of-management-of-metastatic-colorectal-cancer-in-australia
#20
Lewis Au, Natalie Turner, Hui-Li Wong, Kathryn Field, Belinda Lee, David Boadle, Prasad Cooray, Deme Karikios, Suzanne Kosmider, Lara Lipton, Louise Nott, Phillip Parente, Jeanne Tie, Ben Tran, Rachel Wong, Desmond Yip, Jeremy Shapiro, Peter Gibbs
AIM: Current efforts to understand patient management in clinical practice are largely based on clinician surveys with uncertain reliability. The TRACC (Treatment of Recurrent and Advanced Colorectal Cancer) database is a multisite registry collecting comprehensive treatment and outcome data on consecutive metastatic colorectal cancer (mCRC) patients at multiple sites across Australia. This study aims to determine the accuracy of oncologists' impressions of real-word practice by comparing clinicians' estimates to data captured by TRACC...
March 16, 2017: Asia-Pacific Journal of Clinical Oncology
keyword
keyword
27670
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"